Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis

Clinical Biochemistry

Volumn 45, Issue 1-2, 2012, Pages 26-30

  Miller, Elzbieta ^a   Walczak, Anna ^c   Saluk, Joanna ^b   Ponczek, Michał B ^b   Majsterek, Ireneusz ^c  

^a III General Hospital in Lodz   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

3 Nitrotyrosine; Carbonyl groups; Multiple sclerosis; Oxidative stress; Uric acid

Indexed keywords

3 NITROTYROSINE; CARBONYL DERIVATIVE; PLASMA PROTEIN; URIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NITROSATIVE STRESS; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; BLOOD PROTEINS; BLOOD-BRAIN BARRIER; CARBON; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OXIDATIVE STRESS; OXYGEN; REACTIVE OXYGEN SPECIES; TYROSINE; URIC ACID;

EID: 84855301917     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.09.021     Document Type: Article

References (31)

1. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
2. Miller E. Multiple sclerosis. Neurodegenerative diseases 2011, Springer Lands Bioscience. S.I. Ahmad (Ed.).
3. Pokryszko-Dragan A., Gruszka E., Bilińska M. Secondary progressive multiple sclerosis-clinical course and potential predictive factors. Neurol Neurochir Pol 2008, 42:6-11.
4. Frischer J.M., Bramow S., Dal-Bianco A., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
5. Negre-Salvayre A., Coatrieux, Ingueneau C., et al. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. British J Pharm 2008, 153:6-20.
6. Ansari M.A., Roberts K.N., Scheff S.W. Oxidative stress and modification of synaptic proteins in hippocampus after traumatic brain injury. Free Radic Biol Med 2008, 45:443-452.
7. Witherick J., Wilkins A., Scolding N. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis ID 2011, 164608:11.
8. Bizzozero O.A., Callahan K., Pastuszyn A. Elevated protein carbonylation in the brain white matter and grey matter of patients with multiple sclerosis. J Neurosci Res 2005, 5:686-695.
9. Zheng J., Bizzozero O.A. Accumulation of protein carbonyls within cerebellar astrocytes in murine experimental autoimmune encephalomyelitis. J Neurosci Res 2010, 88:3376-3385.
10. Lubin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis results of an international survey. National Multiple Sclerosis Society USA Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
11. Khan J., Brennan D.M., Bradley, et al. 3-Nitrotyrosine in the proteins of human plasma determinate by an ELISA method. Biochem J 1998, 330:795-801.
12. Dietrich-Muszalska A., Olas B., Głowacki R., et al. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 2009, 59:1-7.
13. Buss H., Chan T.P., Sluis K.B., et al. Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997, 23:361-366.
14. Levine R.L., Garland D., Oliver C.N., et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
15. Zheng J., Bizzozero O.A. Decreased activity of the 20S proteasome in the brain white matter and gray matter of patients with multiple sclerosis. J Neurochem 2011, 117:143-153.
16. Zabaleta M., Marino R., Borges J., et al. Activity profile in multiple sclerosis: an integrative approach. A preliminary report. Mult Scler 2002, 8:343-349.
17. Miller E., Mrowicka M., Saluk-Juszczak J., et al. The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 2011, 36:1012-1016.
18. Calabrese V., Cornelius C., Rizzarelli E., et al. Nitric oxide in cell survival: a jams molecule. Antioxid Redox Signal 2009, 11:2717-2739.
19. Chang R.C.C., Rota Ch., Glover R.E., et al. A novel effects of an opioid receptor antagonist, naloxone, on the production of reactive oxygen species by microglia a study by electron paramagnetic resonance spectroscopy. Brain Res 2000, 854:224-229.
20. Bishop A., Hobbs K.G., Equchi A., et al. Differential sensivity of oligodendrocytes and motor neurons to reactive nitrogen species: implications for multiple sclerosis. J Neurochem 2009, 109:93-104.
21. Calabrese V., Scapagnini Ravagna, et al. Nitric oxide synthetase is present in the cerebrospinal fluid of patients with active multiple sclerosis and is associated with increases in cerebrospinal fluid protein nitrotyrosine and S-nitrosothiols and changes in glutathione levels. J Neurosci 2002, 70:580-587.
22. Gonsette R. Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?. Mult Scler 2008, 14:22-34.
23. Squadrito G.L., Cueto R., Splenser A.E., et al. Reaction of uric acid with peroxinitrite and implications for the mechanisms of neuroprotection by uric acid. Arch Biochem Biophys 2000, 376:333-337.
24. Karg E., Klivényi P., Németh I., et al. Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 1999, 246:533-539.
25. Amorini A.M., Petzold A., Tavazzi B., Eikelenboom J., et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 2009, 42:1001-1006.
26. Hooper D.C., Spitsin S., Kean R.B., et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998, 95:675-680.
27. Guerrero A.L., Gutierrez F., Iglesias F., et al. Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 2011, 32:347-350.
28. Rentzos M., Nikolaou C., Anagnostouli M., et al. Serum uric acid and multiple sclerosis. Ciln Neurol Neurosurg 2006, 108:527-531.
29. Miller E., Mrowicka M., Malinowska, et al. Effects of whole body cryotherapy on total antioxidative status and activities of antioxidative enzymes in blood of patients with multiple sclerosis. J Med Invest 2010, 57:168-173.
30. Miller E., Mrowicka M., Malinowska, et al. Effects of whole body cryotherapy on oxidative stress in multiple sclerosis patients. J Therm Biol 2010, 35:406-410.
31. Miller E., Mrowicka M., Malinowska K., et al. Effects of whole body cryotherapy on a total antioxidative status and activity of antioxidant enzymes in blood of depressive multiple sclerosis patients. World J Biol Psychiatry 2011, 12:223-227.